



Belgian Cancer Registry

CANCER FACT SHEET 2023

CORPUS UTERI CANCER

ICD-10 C54







Key facts

- **5th** most common cancer in females
- **1,410** new diagnoses in 2023
- **261** deaths due to corpus uteri cancer in 2021
- 5-year net survival of **81.8%**

Lifetime risk (0-84 years)




2.1 in 100 females






Age-specific incidence, 2019-2023,
and mortality, 2017-2021




- Median age at diagnosis for cancer of the corpus uteri is **71 years**
- The majority of cancers of the corpus uteri are diagnosed in an **early stage** (stage I)
- **Endometrioid carcinoma** is the most common histological subtype of cancer of the corpus uteri
- Stage distribution differs between histological subtypes

Stage distribution




Excluding unregistered stage (3.6%)

Stage distribution by age




Excluding unregistered stage

Histological subtype in corpus uteri cancer




Stage distribution by histological subtype



Excluding unregistered stage




Age-standardised incidence and mortality, 2004-2023




- **95.7%** of cancers of the corpus uteri arises from the **endometrium**
- Risk of a corpus uteri cancer **diagnosis is decreasing** with an average annual percentage change of **-1.3%**
- The average annual percentage change of the risk of **mortality** due to a corpus uteri cancer is **+0.4%**
- This decrease in cancer incidence is specifically seen in the **age group 55-74 years**

Age-standardised incidence trends




Incidence by histological subtype, 2004-2023





Net survival by histological subtype, 2014-2023




- **5-year net survival has been improving** for endometrioid carcinomas in the last 20 years
- Diagnosis in **an early stage** is associated with a **better prognosis**
- More than **16,000 people** are living with the consequences of cancer of the corpus uteri


Additional detailed information (including prevalence) can be found in the [Appendix of the Cancer Fact Sheet](#) and on the [website of the Belgian Cancer Registry](#)



5-year net survival over time in endometrioid carcinoma



5-year net survival over time in serous carcinoma



5-year net survival, 2019-2023, % (95% CI)								
Stage	Corpus Uteri		Endometrioid carcinoma		Serous carcinoma		Other and unspecified	
All	81.8%	(80.1%; 83.5%)	92.6%	(90.7%; 94.6%)	49.7%	(44.3%; 55.8%)	54.3%	(50.3%; 58.7%)
I	97.4%	(95.5%; 99.3%)	101.0%	(99.0%; 103.0%)	80.1%	(71.9%; 89.3%)	80.8%	(75.2%; 86.9%)
II	78.2%	(71.0%; 86.0%)	90.1%	(82.3%; 98.6%)	65.6%	(45.9%; 93.8%)	47.7%	(33.4%; 68.0%)
III	62.7%	(57.6%; 68.1%)	77.4%	(70.7%; 84.9%)	40.9%	(31.5%; 53.2%)	42.8%	(34.5%; 53.2%)
IV	19.0%	(14.6%; 24.7%)	26.7%	(19.7%; 36.1%)	15.2%	(8.4%; 27.6%)	14.4%	(8.8%; 23.4%)
X	36.0%	(28.7%; 45.1%)	43.0%	(31.6%; 58.4%)	FU<5y		37.4%	(27.3%; 51.1%)

Note: Survival results are not shown due to limited follow-up throughout the period, as indicated by FU<kyears in the table. Net survival can exceed 100%; more information in 'Concepts & Abbreviations' (last page)



- **Absolute numbers (N):** The number of newly registered cancer diagnoses observed for a given period of time. All figures and numbers in this cancer fact sheet are based on diagnoses of Belgian residents.
- **Cancer maps:** Cities with at least 150,000 inhabitants are directly represented on the map as circles with a diameter relative to the population size, and a colour shading indicating the actual calculated ESR2013 in that city. The 19 municipalities of the Brussels Capital Region (more than 1,000,000 inhabitants) are divided in three separate circles, based on socio-economic parameters. The socio-economic status is lowest in the westernmost circle and highest in the easternmost circle. Methodological information is available in 'Cancer burden in Belgium 2004-2017, Belgian Cancer Registry, Brussels, 2020'.
- **Crude Rate (CR):** The crude rate is obtained by dividing the absolute number of diagnoses (N) by the corresponding population size at risk (N/100,000).
- **ESR2013:** Incidence rates standardised to the 2013 revised European Standard Population (ESP): Standardisation is necessary to accommodate for differences in population size and age distribution (over time or among regions). An important factor in interpreting trends in cancer incidence is population ageing, as cancer is an age-dependent disease. For a higher proportion of elderly people in the population, a higher total number of cancer diagnoses can be expected for the same cancer risk. When only absolute numbers (N) or Crude Rate (CR) results are used, a misleading picture of the actual changes in the risk of a cancer diagnosis could be obtained. Therefore, direct standardisation is necessary to evaluate the evolution of the risk of cancer diagnosis over time or among regions.
- **Net survival:** Often also called the relative survival, is an estimate of the survival probability when other causes of death beside the cancer type(s) under study are excluded. As examples of other causes of death, patients with the cancer type(s) under study could also die because of an accident or unrelated cardiac conditions, etc. Net survival may exceed 100%, this occurs when the observed survival probability for patients with the cancer type(s) under study is higher than the one for the matched general population (no excess mortality due to cancer).
- The net survival estimation was based on the regional lifetables 2023, obtained from Statbel.
- **Stage:** Cancers are reported with a stage, labelled with a Roman numeral with IV being the most advanced stage. Stage is based on the T-category (extent of the tumour), the N-category (absence or presence and extent of the regional lymph node metastasis) and the M-category (absence or presence of distant metastasis). Stage is reported as a combination of both clinical and pathological stage with priority given to the pathological stage. Clinical information about distant metastases (cM) will always be taken into account, and in case of neo-adjuvant therapy, priority is given to the clinical stage. If stage is unknown, not applicable or not submitted to the Belgian Cancer Registry, the stage is reported as 'unregistered stage'. Stage is reported according to the TNM 8th edition: J.D. Brierley, M.K. Gospodarowicz, Ch. Wittekind. TNM Classification of Malignant Tumours, 8th edition: UICC, 2017.
- **95% CI:** 95% Confidence Intervals are indicated with a shaded band or whiskers in the figures. The 95% CI is a range of values that has 95% chance to contain the true mean value.

**Mortality statistics in Belgium are collected and managed by the three Regions (Flemish Region: Departement Zorg; Brussels-Capital Region: Observatorium voor Gezondheid en Welzijn van Brussel-Hoofdstad/ l'Observatoire de la Santé et du Social de Bruxelles-Capitale; Walloon Region: Agence Wallonne de la Santé, de la Protection sociale, du Handicap et des Familles (AVIQ)). The Directorate General Statistics Belgium is responsible for collecting and merging the data coming from the regional agencies. Mortality data used in this cancer fact sheet are collected from the Directorate General Statistics Belgium and encompasses the period 2004-2021.*

Recommended reference: Cancer Fact Sheets 2023, Belgian Cancer Registry (BCR), 2025